Richard M Goldberg

Richard M Goldberg, MD retired from academic medicine in December of 2019. He worked as a practicing oncologist, clinical trialist, and cancer center executive at multiple centers including Mayo Clinic, UNC, OSU, and WVU. Now he is engaging with both start-up and well-established pharmaceutical and technology companies on drug and biomarker development, as an expert witness in patent law disputes, and by serving on data safety monitoring boards. He remains the editor for GI cancers for UpToDate, He continues to serve as the Associate Group Chair for the NCI funded oncology cooperative group the Alliance. He is the chair of the Lower GI Committee of the American Joint Commission on Cancer that is revising the AJCC Staging Manual for the 9^th edition. He also continues to mentor GI oncologists locally, around the country, and across the world giving early, mid-career, and senior academic physicians and administrative physicians research and career advice. Considered an international leader in gastrointestinal cancer treatment and research as well as in leadership of cancer programs in academic medicine, Dr. Goldberg has been principal investigator, co-PI, co-investigator and mentor on multiple research and training grants funded through the National Cancer Institute (NCI). He has published more than 450 papers in peer-reviewed journals. He led the phase III trial that provided the data that led to the Food and Drug Administration’s licensing of oxaliplatin as indicated for the treatment of metastatic colorectal cancer in collaboration with collaborators from Sanofi. The FOLFOX regimen remains the standard of care in that setting 20 years later. His research focuses on defining new treatments, elucidating inherited cancer susceptibility, development of new technologies and identification of predictive and prognostic factors in GI cancers. Dr. Goldberg is a graduate of Harvard University, earning an undergraduate degree cum laude in biology in 1975 and received his medical degree from the State University of New York Upstate Medical University in 1979 where he was elected to the Alpha Omega Alpha honor medical society. He completed his residency at Emory University and his medical oncology fellowship at Georgetown University. He is a member of the board of directors of Fight Colorectal Cancer, a patient advocacy organization. He has been honored as a Fellow in the American College of Physicians and the American Society of Clinical Oncology.